A61K 2039/884
Prostate
Official title: {prostate}
A61K2039/884 (Prostate) appears on 73 US grants and 148 published applications in this corpus.
Search patents in A61K- Granted patents
- 73
- Published applications
- 148
- Assignees
- 81
- Inventors
- 271
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 1 | 2 |
| 2005 | 1 | 3 |
| 2006 | 0 | 1 |
| 2007 | 1 | 2 |
| 2008 | 1 | 2 |
| 2009 | 0 | 1 |
| 2010 | 1 | 1 |
| 2011 | 2 | 0 |
| 2012 | 1 | 3 |
| 2013 | 2 | 5 |
| 2014 | 2 | 2 |
| 2015 | 2 | 2 |
| 2016 | 3 | 3 |
| 2017 | 1 | 4 |
| 2018 | 3 | 4 |
| 2019 | 2 | 12 |
| 2020 | 2 | 10 |
| 2021 | 5 | 20 |
| 2022 | 2 | 16 |
| 2023 | 12 | 12 |
| 2024 | 10 | 26 |
| 2025 | 13 | 10 |
| 2026 | 6 | 7 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Intracellular delivery of biomolecules to modify immune response8 Sep 2026US 12,728,163 B2Stemcell Technologies Canada Inc.
- Prostate neoantigens and their uses28 Jul 2026US 12,692,513 B2Janssen Biotech, Inc.
- Compositions and methods of treatment comprising tumor-targeting bacteria and chemotherapy or immunotherapy agent9 Jun 2026US 12,648,970 B2The Curators of the University of Missouri
- Immunostimulatory bacteria for the treatment of cancer28 Apr 2026US 12,611,432 B2Northwestern University
- Prostate neoantigens and their uses24 Mar 2026US 12,582,683 B2Janssen Biotech, Inc.
- Tumor cell vaccines20 Aug 2026US 2026/0240969 A1Neuvogen, Inc.
- Chimeric antigen receptors targeted to psca20 Aug 2026US 2026/0242509 A1City of Hope
- Prostate neoantigens and their uses23 Jul 2026US 2026/0207689 A1
- Chimeric Receptors to STEAP1 and Methods Of Use Thereof2 Jul 2026US 2026/0184816 A1Amgen Inc.
- Mrna, mrna vaccine formulation, and preparation method and use thereof18 Jun 2026US 2026/0166134 A1Panru Biotechnology (Tianjin) Co., Ltd
Most cited
By later US patents
- Cancer treatments13US 6,699,483 B1Onyvax Limited · 2004
- Methods and compositions for treating prostate cancer using DNA vaccines12US 7,179,797 B2Wisconsin Alumni Research Foundation · 2007
- Combination of a PD-1 antagonist and a listeria-based vaccine for treating prostate cancer12US 9,907,849 B2Advaxis, Inc. · 2018
- Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same10US 8,927,692 B2Inovio Pharmaceuticals, Inc. · 2015
- Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers7US 10,400,011 B2Immatics Biotechnologies GmbH · 2019